Coronado Biosciences is focused on developing novel immunotherapy biologic agents. The company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information visit the company’s Web site at www.coronadobiosciences.com
Let us hear your thoughts below: